Nathaniel Melling1, Ronald Simon2, Martina Mirlacher2, Jakob R Izbicki1, Philip Stahl2, Luigi M Terracciano3, Carsten Bokemeyer4, Guido Sauter2, Andreas H Marx2. 1. Department of Surgery, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. 2. Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. 3. Institute of Pathology, University Hospital Basel, Basel, Switzerland. 4. Department of Oncology, Haematology, BMT with section Pneumology, Hubertus Wald Cancer Centre, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Abstract
AIMS: RNA-binding motif protein 3 (RBM3) has recently been suggested as a prognostic biomarker in an array of human cancers. This study aimed to examine its effects in colorectal cancers. METHODS AND RESULTS: RBM3 expression was analysed by immunohistochemistry on a tissue microarray containing 1800 colorectal cancers (CRCs). Nuclear RBM3 immunohistochemical staining was found in 95.9% of all interpretable CRCs. Loss of RBM3 expression was linked to advanced tumour stage (P < 0.0001), right-sided tumour localization (P < 0.0001), and poor prognosis (P = 0.0003). In a multivariable analysis including RBM3 staining, tumour grade, tumour stage, and nodal status, only tumour stage and nodal status proved to be independent prognostic markers (P < 0.0001 each), whereas the prognostic impact of RBM3 staining was not significant (P = 0.2655). CONCLUSIONS: Our observations indicate that loss of RBM3 expression is an unfavourable prognostic marker in CRC, and is linked to right-sided tumour localization.
AIMS: RNA-binding motif protein 3 (RBM3) has recently been suggested as a prognostic biomarker in an array of humancancers. This study aimed to examine its effects in colorectal cancers. METHODS AND RESULTS:RBM3 expression was analysed by immunohistochemistry on a tissue microarray containing 1800 colorectal cancers (CRCs). Nuclear RBM3 immunohistochemical staining was found in 95.9% of all interpretable CRCs. Loss of RBM3 expression was linked to advanced tumour stage (P < 0.0001), right-sided tumour localization (P < 0.0001), and poor prognosis (P = 0.0003). In a multivariable analysis including RBM3 staining, tumour grade, tumour stage, and nodal status, only tumour stage and nodal status proved to be independent prognostic markers (P < 0.0001 each), whereas the prognostic impact of RBM3 staining was not significant (P = 0.2655). CONCLUSIONS: Our observations indicate that loss of RBM3 expression is an unfavourable prognostic marker in CRC, and is linked to right-sided tumour localization.
Authors: Christina Siesing; Halfdan Sorbye; Anca Dragomir; Per Pfeiffer; Camilla Qvortrup; Fredrik Pontén; Karin Jirström; Bengt Glimelius; Jakob Eberhard Journal: PLoS One Date: 2017-08-11 Impact factor: 3.240
Authors: Katharina Grupp; Bianca Hofmann; Asad Kutup; Kai Bachmann; Dean Bogoevski; Nathaniel Melling; Faik Guntac Uzunoglu; Alexander Tarek El Gammal; Christina Koop; Ronald Simon; Stefan Steurer; Till Krech; Susanne Burdak-Rothkamm; Frank Jacobsen; Guido Sauter; Jakob Izbicki; Waldemar Wilczak Journal: BMC Cancer Date: 2018-11-12 Impact factor: 4.430
Authors: Jennyfer M García-Cárdenas; Santiago Guerrero; Andrés López-Cortés; Isaac Armendáriz-Castillo; Patricia Guevara-Ramírez; Andy Pérez-Villa; Verónica Yumiceba; Ana Karina Zambrano; Paola E Leone; César Paz-Y-Miño Journal: Front Mol Biosci Date: 2019-08-07
Authors: Annette Salomonsson; Patrick Micke; Johanna S M Mattsson; Linnea La Fleur; Johan Isaksson; Mats Jönsson; Björn Nodin; Johan Botling; Mathias Uhlén; Karin Jirström; Johan Staaf; Maria Planck; Hans Brunnström Journal: Cancer Med Date: 2020-06-03 Impact factor: 4.452